论文部分内容阅读
目的:观察扶正肺瘤方对肺癌患者CD4+CD25+Treg细胞的影响。方法:将50例患者随机分为观察组和对照组,每组各25例。对照组单纯给予DP方案化疗(多西紫杉醇联合顺氯氨铂),观察组在对照组的基础上加服扶正肺瘤方,两组均在治疗2个疗程(3周为1个疗程)后通过流式细胞术检测患者外周血免疫细胞,比较观察组和对照组CD4+CD25+Treg免疫细胞检测值,同时比较每组治疗前后免疫细胞功能变化情况。结果:治疗前两组外周血CD4+CD25+Treg细胞百分率无明显差异(P>0.05);2个疗程后,两组患者外周血CD4+CD25+Treg细胞的表达较治疗前均明显下降,差异有统计学意义(P<0.05);观察组下降更为明显,与对照组比较有显著性差异(P<0.05)。观察组T细胞及NK细胞活性均有提高,且均明显优于对照组(P<0.05)。结论:扶正肺瘤方可下调晚期非小细胞肺癌患者CD4+CD25+,调节性T细胞的表达水平,从而有助于恢复机体对肿瘤的免疫监视能力。
Objective: To observe the effect of Fuzheng Feiliu recipe on CD4+CD25+Treg cells in lung cancer patients. Methods: Fifty patients were randomly divided into observation group and control group, 25 cases in each group. The control group was given only DP regimen chemotherapy (docetaxel plus cisplatin), the observation group was treated with Fuzheng Lung Tumor on the basis of the control group, and both groups were treated after 2 courses (3 weeks as 1 course of treatment). The peripheral blood immune cells were detected by flow cytometry, and the CD4+CD25+Treg immune cells were compared between the observation group and the control group. The changes of immune cell function before and after treatment were compared. Results: There was no significant difference in the percentage of CD4+CD25+ Treg cells in the peripheral blood of the two groups before treatment (P>0.05). After two courses of treatment, the expression of CD4+CD25+ Treg cells in the peripheral blood of both groups was significantly lower than before treatment. There was statistical significance (P<0.05); the observation group decreased more significantly, and there was a significant difference compared with the control group (P<0.05). The activity of T cells and NK cells in the observation group increased, and all of them were significantly better than the control group (P<0.05). Conclusion: Fuzheng lung tumor can down-regulate the expression of CD4+CD25+ and regulatory T cells in patients with advanced non-small cell lung cancer, which helps to restore the body’s immune surveillance ability to tumors.